Sab Biotherapeutics(NASDAQ) SABS

SAB Biotherapeutics uses modified cows to make medicines for people with serious health conditions. These treatments help patients manage diseases like Type 1 diabetes and the flu. The company creates human-like antibodies without needing blood from human donors.

What Is SAB Developing?

• SAB-142: Lead candidate for Type 1 diabetes designed to slow or stop the progression of the disease; currently in development.
• SAB-176: Human antibody medicine focused on treating or preventing severe cases of influenza.
• SAB-185: Polyclonal antibody therapeutic candidate that reached Phase III clinical trials for the treatment of COVID-19.
• DiversitAb Platform: Proprietary technology using genetically engineered bovine herds to produce fully human antibodies for various immune disorders.

Recent Strategic Moves

• March 2026 Public Offering: Raised approximately $86.4 million in net proceeds to fund operations and clinical development.
• July 2025 Series B: Secured $175 million in gross proceeds through a private placement involving preferred stock and warrants.
• SAB Australia: Established a subsidiary in June 2023 to perform clinical activities and access local research tax credits.
• Ladenburg Thalmann & Co.: Resolved legal proceedings in March 2023 through a settlement involving cash and stock warrants.

How the Company Stands Out

The company uses transchromosomic cows, which are animals genetically engineered to produce fully human antibodies instead of bovine ones. This allows the production of polyclonal antibodies that can target multiple sites on a specific disease simultaneously.

Recent Financial Results

• Net loss reached $18.9 million in Q1 2026, worsening by 263.1% from a $5.2 million loss in Q1 2025.
• Operating loss was $20 million in Q1 2026, worsening by 85.6% from $10.8 million in the prior year period.
• Free cash flow was negative $14.3 million in Q1 2026, worsening from negative $7.8 million in Q1 2025.
• Cash and cash equivalents grew to $20.5 million by March 31, 2026, up from $10.5 million at the end of 2025.

The Bottom Line

SAB Biotherapeutics has evolved from an early research firm into a clinical-stage developer focused on its unique bovine-based antibody platform. The company continues to rely on significant equity offerings to fund the progression of its Type 1 diabetes and infectious disease programs.